Abstract: The present disclosure provides constructs comprising a coding sequence operably linked to a promoter, wherein the coding sequence encodes a pendrin protein. Exemplary constructs include AAV constructs. Also provided are methods of using disclosed constructs for the treatment of hearing loss and/or deafness.

Abstract: A composition for treating Fabry disease, which includes a polynucleotide having gene editing function for correction of the specific mutation (IVS4+919 G>A) of GLA gene. A method for treating Fabry disease, which uses gene editing systems for correction of the specific mutation (IVS4+919 G>A) of GLA gene in Fabry disease.

Abstract: The present disclosure pertains to a method for diagnosing a middle ear disease comprising receiving one or more otoscopic image of a subject, pre-processing the one or more otoscopic image to obtain image data, inputting the image data to a trained network model, generating, using the trained network model, an output that characterizes the health of the subject with respect to the middle ear disease, and generating a diagnostic result based on the output, wherein the trained network model is based on a model selected from the group consisting of a MobileNetV2 model, a NASNetMobile model, and a DenseNet201 model.

Abstract: The present disclosure provides compositions and methods for treating subjects at risk for or with sensorineural hearing loss by modulating the rate of Atoh1 protein degradation to increase levels of Atoh1 protein.

Abstract: The present invention provides a computer-implanted method and system for diagnosing sudden sensorineural hearing loss (SSNHL) of an ear in a subject; comprising on one or more processors of the computer the steps of: testing the hearing of two ears of the subject, and calculating the difference between them; and comparing the difference with a threshold to diagnose the subject as SSNHL or not.

Abstract: The present disclosure provides compositions and methods for treating subjects at risk for or with sensorineural hearing loss by modulating the rate of Atoh1 protein degradation to increase levels of Atoh1 protein.

Abstract: The present invention provides a method for treating an auditory neuropathy spectrum disorder in a subject comprising transferring the gene of DFNB59 via an adeno-associated virus (AAV) vector to the subject.

Abstract: The present invention provides a method for treating a method for treating an auditory neuropathy spectrum disorder in a subject comprising transferring a transgene via an adeno-associated virus (AAV) vector to the subject; wherein the transgene is selected from the group consisting of Pjvk, PCDH15, GJB2, DIAPH3, PCDH9, SLC17A8, AIFM1, AND OTOF.

Abstract: The present disclosure provides compositions and methods for treating subjects at risk for or with sensorineural hearing loss by modulating the rate of Atoh1 protein degradation to increase levels of Atoh1 protein.

Abstract: The present disclosure provides compositions and methods for treating subjects at risk for or with sensorineural hearing loss by modulating the rate of Atoh1 protein degradation to increase levels of Atoh1 protein.